文献速递腹部技术与安全USMR

9项定量超声参数诊断和分级非酒精性脂肪肝患者肝脏脂肪变性的效能

Diagnostic Performance of 9 Quantitative Ultrasound Parameters for Detection and Classification of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease.
PubMed 文献 · Invest Radiol · 2022-01-01

该前瞻性研究纳入31例NAFLD或疑似NAFLD患者,以MRI-PDFF为参考标准,评估9项定量超声参数诊断和分级肝脂肪变性的能力。结果显示AC、SI、Nakagami、SS、HRI和MBF与MRI-PDFF强相关,在6.4%、17.4%和22.1%三个MRI-PDFF阈值下AUC达0.85~1;而剪切波弹性、粘度和频散相关性弱、诊断效能差。

要点

  • AC、SI、Nakagami、SS、HRI和MBF与MRI-PDFF强相关,可用于检测和分级肝脂肪变性。
  • 以MRI-PDFF 6.4%、17.4%、22.1%为阈值时,上述参数AUC范围为0.85~1。
  • 剪切波弹性、粘度和频散与MRI-PDFF相关性弱,诊断效能差。

核心结论

  • AC、Nakagami、SI、SS、MBF和HRI与MRI-PDFF相关性最好,在该研究人群中检测和分级肝脂肪变性具有高诊断效能。
  • 定量超声可作为基于MRI技术评估NAFLD患者或高危人群肝脂肪变性的准确替代方法。

研究设计与样本

  • 前瞻性研究,经机构审查委员会批准并符合HIPAA,纳入31例NAFLD或疑似NAFLD且无其他慢性肝病患者(13男18女,平均年龄52岁,范围26~90岁)。
  • 以MRI估计的质子密度脂肪分数(MRI-PDFF)为参考标准,评估9项定量超声参数的诊断效能。
  • 诊断效能以ROC曲线下面积和准确率评估,对照MRI-PDFF阈值6.4%、17.4%和22.1%;与MRI-PDFF的线性关系用Spearman相关系数评估。

诊断标准与关键数值

  • AC、SI、Nakagami、SS、HRI和MBF与MRI-PDFF的Spearman相关系数分别为0.89、0.89、0.88、-0.87、0.81和0.71(P<0.01)。
  • 以MRI-PDFF 6.4%、17.4%和22.1%为阈值识别肝脂肪变性时,上述参数的AUC范围为0.85~1。
  • 剪切波弹性、剪切波粘度和剪切波频散与MRI-PDFF的相关系数分别为0.45、0.38和0.07,诊断效能差。

临床应用与阅片要点

  • 在NAFLD或疑似NAFLD患者中,可优先关注AC、Nakagami、SI、SS、MBF和HRI等与MRI-PDFF强相关的定量超声参数。
  • 剪切波弹性、粘度和频散不宜单独用于评估肝脂肪变性程度。
  • 本研究为初步结果,定量超声参数用于临床分级前需在更大样本中验证。

局限性

  • 样本量仅31例,属初步研究,结果需更大样本验证。
  • 单中心前瞻性研究,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease worldwide. Quantitative ultrasound (QUS) parameters based on radiofrequency raw data show promise in quantifying liver fat.

PURPOSE: The aim of this study was to evaluate the diagnostic performance of 9 QUS parameters compared with magnetic resonance imaging (MRI)-estimated proton density fat fraction (PDFF) in detecting and staging hepatic steatosis in patients with or suspected of NAFLD.

MATERIALS AND METHODS: In this Health Insurance Portability and Accountability Act-compliant institutional review board-approved prospective study, 31 participants with or suspected of NAFLD, without other underlying chronic liver diseases (13 men, 18 women; average age, 52 years [range, 26-90 years]), were examined. The following parameters were obtained: acoustic attenuation coefficient (AC); hepatorenal index (HRI); Nakagami parameter; shear wave elastography measures such as shear wave elasticity, viscosity, and dispersion; and spectroscopy-derived parameters including spectral intercept (SI), spectral slope (SS), and midband fit (MBF). The diagnostic ability (area under the receiver operating characteristic curves and accuracy) of QUS parameters was assessed against different MRI-PDFF cutoffs (the reference standard): 6.4%, 17.4%, and 22.1%. Linearity with MRI-PDFF was evaluated with Spearman correlation coefficients (p).

RESULTS: The AC, SI, Nakagami, SS, HRI, and MBF strongly correlated with MRI-PDFF (P = 0.89, 0.89, 0.88, -0.87, 0.81, and 0.71, respectively [P < 0.01]), with highest area under the receiver operating characteristic curves (ranging from 0.85 to 1) for identifying hepatic steatosis using 6.4%, 17.4%, and 22.1% MRI-PDFF cutoffs. In contrast, shear wave elasticity, shear wave viscosity, and shear wave dispersion did not strongly correlate to MRI-PDFF (P = 0.45, 0.38, and 0.07, respectively) and had poor diagnostic performance.

CONCLUSION: The AC, Nakagami, SI, SS, MBF, and HRI best correlate with MRI-PDFF and show high diagnostic performance for detecting and classifying hepatic steatosis in our study population.

SUMMARY STATEMENT: Quantitative ultrasound is an accurate alternative to MRI-based techniques for evaluating hepatic steatosis in patients with or at risk of NAFLD.

KEY FINDINGS: Our preliminary results show that specific quantitative ultrasound parameters accurately detect different degrees of hepatic steatosis in NAFLD.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Pirmoazen AM, Khurana A, Loening AM, et al. Diagnostic Performance of 9 Quantitative Ultrasound Parameters for Detection and Classification of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease. Invest Radiol. 2022. PMID: 34049335. doi:10.1097/RLI.0000000000000797

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。